Hospira launches first biosimilar MAb in major European markets

Hospira has launched the first biosimilar monoclonal antibody, Inflectra, in major European markets. Inflectra, a biosimilar medicine to the reference product Remicade(R) (infliximab), is licensed for the treatment of inflammatory conditions including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, adult and pediatric ulcerative colitis and plaque psoriasis. The product is being launched in several major European markets, including Austria, Denmark, France, Germany, Greece, Italy, Luxembourg, Netherlands, Spain and Sweden. Hospira's partner, Celltrion, has also submitted an application for the product to the FDA (Hospira News Release).